Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.61)
# 226
Out of 5,055 analysts
138
Total ratings
50.41%
Success rate
42.96%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $6.97 | +129.56% | 20 | Nov 10, 2025 | |
| CYTK Cytokinetics | Reiterates: Buy | $80 → $90 | $66.44 | +35.46% | 5 | Nov 10, 2025 | |
| ZYME Zymeworks | Initiates: Buy | $30 | $18.52 | +61.99% | 1 | Oct 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $40.79 | +81.42% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $529.21 | +5.82% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $56.68 | +85.25% | 3 | Sep 23, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $31.00 | +77.42% | 14 | Sep 17, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $28 | $17.37 | +61.20% | 1 | Sep 12, 2025 | |
| ACTU Actuate Therapeutics | Initiates: Buy | $20 | $5.91 | +238.41% | 1 | Aug 26, 2025 | |
| ALT Altimmune | Maintains: Buy | $20 → $18 | $4.17 | +331.65% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.55 | +222.58% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.50 | +100.00% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.41 | +393.83% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $11.37 | +75.90% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.88 | +59.57% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $17.44 | +100.69% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $41.26 | -7.90% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $39.11 | +145.46% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.55 | -3.23% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $27.61 | +19.52% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $17.69 | +691.41% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.66 | +2,359.02% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $4.33 | +3,595.15% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $2.83 | +76.68% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.76 | +1,494.20% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.62 | +3,335.11% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.42 | +392.96% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.22 | +368,752.46% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.50 | +179,900.00% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $7.27 | +959.15% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.04 | +138,361.54% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $5.51 | -27.40% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $98.81 | -60.53% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $4.25 | +700.00% | 1 | Mar 13, 2020 |
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $6.97
Upside: +129.56%
Cytokinetics
Nov 10, 2025
Reiterates: Buy
Price Target: $80 → $90
Current: $66.44
Upside: +35.46%
Zymeworks
Oct 10, 2025
Initiates: Buy
Price Target: $30
Current: $18.52
Upside: +61.99%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $40.79
Upside: +81.42%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $529.21
Upside: +5.82%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $56.68
Upside: +85.25%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $31.00
Upside: +77.42%
Theravance Biopharma
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $17.37
Upside: +61.20%
Actuate Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $5.91
Upside: +238.41%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.17
Upside: +331.65%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.55
Upside: +222.58%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.50
Upside: +100.00%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.41
Upside: +393.83%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $11.37
Upside: +75.90%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.88
Upside: +59.57%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $17.44
Upside: +100.69%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $41.26
Upside: -7.90%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $39.11
Upside: +145.46%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.55
Upside: -3.23%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $27.61
Upside: +19.52%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $17.69
Upside: +691.41%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.66
Upside: +2,359.02%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $4.33
Upside: +3,595.15%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $2.83
Upside: +76.68%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.76
Upside: +1,494.20%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.62
Upside: +3,335.11%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.42
Upside: +392.96%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.22
Upside: +368,752.46%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.50
Upside: +179,900.00%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $7.27
Upside: +959.15%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.04
Upside: +138,361.54%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $5.51
Upside: -27.40%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $98.81
Upside: -60.53%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $4.25
Upside: +700.00%